179 related articles for article (PubMed ID: 28903424)
1. Identification and characterization of a novel
Milione M; Ardini E; Christiansen J; Valtorta E; Veronese S; Bosotti R; Pellegrinelli A; Testi A; Pietrantonio F; Fucà G; Wei G; Murphy D; Siena S; Isacchi A; De Braud F
Oncotarget; 2017 Aug; 8(33):55353-55360. PubMed ID: 28903424
[TBL] [Abstract][Full Text] [Related]
2. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
Sartore-Bianchi A; Ardini E; Bosotti R; Amatu A; Valtorta E; Somaschini A; Raddrizzani L; Palmeri L; Banfi P; Bonazzina E; Misale S; Marrapese G; Leone A; Alzani R; Luo D; Hornby Z; Lim J; Veronese S; Vanzulli A; Bardelli A; Martignoni M; Davite C; Galvani A; Isacchi A; Siena S
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26563355
[TBL] [Abstract][Full Text] [Related]
4. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.
Lee SJ; Li GG; Kim ST; Hong ME; Jang J; Yoon N; Ahn SM; Murphy D; Christiansen J; Wei G; Hornby Z; Lee DW; Park JO; Park YS; Lim HY; Hong SN; Kim SH; Kang WK; Park K; Park WY; Kim KM; Lee J
Oncotarget; 2015 Nov; 6(36):39028-35. PubMed ID: 26472021
[TBL] [Abstract][Full Text] [Related]
5. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
Rolfo C; Ruiz R; Giovannetti E; Gil-Bazo I; Russo A; Passiglia F; Giallombardo M; Peeters M; Raez L
Expert Opin Investig Drugs; 2015; 24(11):1493-500. PubMed ID: 26457764
[TBL] [Abstract][Full Text] [Related]
6. Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma.
Créancier L; Vandenberghe I; Gomes B; Dejean C; Blanchet JC; Meilleroux J; Guimbaud R; Selves J; Kruczynski A
Cancer Lett; 2015 Aug; 365(1):107-11. PubMed ID: 26001971
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
Fuse MJ; Okada K; Oh-Hara T; Ogura H; Fujita N; Katayama R
Mol Cancer Ther; 2017 Oct; 16(10):2130-2143. PubMed ID: 28751539
[No Abstract] [Full Text] [Related]
8. Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers.
Ukkola I; Nummela P; Kero M; Tammio H; Tuominen J; Kairisto V; Kallajoki M; Haglund C; Peltomäki P; Kytölä S; Ristimäki A
Virchows Arch; 2022 Apr; 480(4):807-817. PubMed ID: 35237889
[TBL] [Abstract][Full Text] [Related]
9. Foretinib Overcomes Entrectinib Resistance Associated with the
Nishiyama A; Yamada T; Kita K; Wang R; Arai S; Fukuda K; Tanimoto A; Takeuchi S; Tange S; Tajima A; Furuya N; Kinoshita T; Yano S
Clin Cancer Res; 2018 May; 24(10):2357-2369. PubMed ID: 29463555
[No Abstract] [Full Text] [Related]
10. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.
Ardini E; Bosotti R; Borgia AL; De Ponti C; Somaschini A; Cammarota R; Amboldi N; Raddrizzani L; Milani A; Magnaghi P; Ballinari D; Casero D; Gasparri F; Banfi P; Avanzi N; Saccardo MB; Alzani R; Bandiera T; Felder E; Donati D; Pesenti E; Sartore-Bianchi A; Gambacorta M; Pierotti MA; Siena S; Veronese S; Galvani A; Isacchi A
Mol Oncol; 2014 Dec; 8(8):1495-507. PubMed ID: 24962792
[TBL] [Abstract][Full Text] [Related]
11. A rare case of recurrent ovarian cancer with
Endo Y; Watanabe T; Saito M; Saito K; Suzuki R; Sano H; Natori Y; Sasaki E; Ueda M; Kamo N; Furukawa S; Soeda S; Kono K; Saji S; Fujimori K
Mol Clin Oncol; 2022 Apr; 16(4):90. PubMed ID: 35251641
[No Abstract] [Full Text] [Related]
12. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
Russo M; Misale S; Wei G; Siravegna G; Crisafulli G; Lazzari L; Corti G; Rospo G; Novara L; Mussolin B; Bartolini A; Cam N; Patel R; Yan S; Shoemaker R; Wild R; Di Nicolantonio F; Bianchi AS; Li G; Siena S; Bardelli A
Cancer Discov; 2016 Jan; 6(1):36-44. PubMed ID: 26546295
[TBL] [Abstract][Full Text] [Related]
13. Activity of Entrectinib in a Patient With the First Reported
Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
[TBL] [Abstract][Full Text] [Related]
14. Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
Konicek BW; Capen AR; Credille KM; Ebert PJ; Falcon BL; Heady GL; Patel BKR; Peek VL; Stephens JR; Stewart JA; Stout SL; Timm DE; Um SL; Willard MD; Wulur IH; Zeng Y; Wang Y; Walgren RA; Betty Yan SC
Oncotarget; 2018 Mar; 9(17):13796-13806. PubMed ID: 29568395
[TBL] [Abstract][Full Text] [Related]
15. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of
Liu D; Offin M; Harnicar S; Li BT; Drilon A
Ther Clin Risk Manag; 2018; 14():1247-1252. PubMed ID: 30050303
[TBL] [Abstract][Full Text] [Related]
16. Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer with NTRK Overexpression.
Sohn SH; Sul HJ; Kim BJ; Kim HS; Zang DY
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008821
[TBL] [Abstract][Full Text] [Related]
17. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
Pacenta HL; Macy ME
Drug Des Devel Ther; 2018; 12():3549-3561. PubMed ID: 30425456
[TBL] [Abstract][Full Text] [Related]
18. Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.
Amatu A; Somaschini A; Cerea G; Bosotti R; Valtorta E; Buonandi P; Marrapese G; Veronese S; Luo D; Hornby Z; Multani P; Murphy D; Shoemaker R; Lauricella C; Giannetta L; Maiolani M; Vanzulli A; Ardini E; Galvani A; Isacchi A; Sartore-Bianchi A; Siena S
Br J Cancer; 2015 Dec; 113(12):1730-4. PubMed ID: 26633560
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells.
Suzuki C; Nishiyama A; Arai S; Tange S; Tajima A; Tanimoto A; Fukuda K; Takumi Y; Kotani H; Takeuchi S; Yanagimura N; Ohtsubo K; Yamamoto N; Omori K; Yano S
Cancer Sci; 2022 Jul; 113(7):2323-2335. PubMed ID: 35363931
[TBL] [Abstract][Full Text] [Related]
20. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Doebele RC; Davis LE; Vaishnavi A; Le AT; Estrada-Bernal A; Keysar S; Jimeno A; Varella-Garcia M; Aisner DL; Li Y; Stephens PJ; Morosini D; Tuch BB; Fernandes M; Nanda N; Low JA
Cancer Discov; 2015 Oct; 5(10):1049-57. PubMed ID: 26216294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
